These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32049359)

  • 1. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
    Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
    Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
    J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
    Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
    Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
    Cuccuini W; Briere J; Mounier N; Voelker HU; Rosenwald A; Sundstrom C; Cogliatti S; Hirchaud E; Ysebaert L; Bron D; Soulier J; Gaulard P; Houlgatte R; Gisselbrecht C; Thieblemont C
    Blood; 2012 May; 119(20):4619-24. PubMed ID: 22408263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
    Thiruvengadam SK; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Results of Rituximab Pre- and Post-BEAM with or without
    Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
    Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study.
    Partanen A; Turunen A; Valtola J; Pyörälä M; Vasala K; Kuittinen O; Kuitunen H; Penttilä K; Keskinen L; Kuittinen T; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Feb; 61(2):516-525. PubMed ID: 33245582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
    Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
    Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
    Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
    Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
    Munshi PN; Chen Y; Ahn KW; Awan FT; Cashen A; Shouse G; Shadman M; Shaughnessy P; Zurko J; Locke FL; Goodman AM; Bisneto JCV; Sauter C; Kharfan-Dabaja MA; Meyers G; Jaglowski S; Herrera A; Hamadani M
    Transplant Cell Ther; 2022 Aug; 28(8):487.e1-487.e7. PubMed ID: 35609865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
    Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
    JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
    Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
    Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
    Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.